FreeDM2 Clinical Trial Proves Continuous Glucose Monitoring Superior to Finger Pricks for Type 2 Diabetes Management

The FreeDM2 trial shows continuous glucose monitoring outperforms finger pricks for type 2 diabetes control, offering a life-changing tool for insulin users.

By: AXL Media

Published: Apr 24, 2026, 6:16 AM EDT

Source: Information for this report was sourced from EurekAlert!

A Technological Shift in Glucose Management

The results of the FreeDM2 clinical trial signal a potential paradigm shift in how patients manage type 2 diabetes, specifically those treated with basal insulin. Researchers found that adults utilizing real-time continuous glucose monitoring, or CGM, experienced substantial improvements in their blood glucose levels compared to those relying on traditional finger prick tests. Dr. Emma Wilmot, a lead researcher from the University of Nottingham, noted that the technology provides patients with immediate insights, allowing for a more proactive approach to a condition that is notoriously difficult to self-manage on a daily basis.

Breaking the Cycle of Finger Prick Monitoring

While finger prick blood tests have long been the standard for guiding diet and activity, CGM offers a less invasive and more comprehensive alternative through a small sensor worn on the arm. This device transmits data directly to a smartphone, providing constant updates and triggering alarms when sugar levels deviate from the target range. According to the study, this constant stream of data addresses the uncertainty that often surrounds type 2 diabetes care, especially when patients are transitioning to newer therapies or managing complex insulin regimens.

Evidence of Sustained Glycemic Improvement

The trial involved 303 participants who were monitored over two distinct phases to test the technology's effectiveness in different care environments. During the initial 16-week self-management period, those equipped with CGM sensors saw significantly greater reductions in their HbA1c levels, a key marker of long-term sugar control. This benefit remained consistent through a second 16-week phase involving clinician guidance, suggesting that the advantages of the technology are not merely temporary but can be maintained through various stages of treatment.